ASCENDIS PHARMA AS (NASDAQ: ASND)

ASCENDIS PHARMA AS

NASDAQ: ASND (Ascendis Pharma A/S)

Last update: yesterday, 1:43AM

119.22

5.41 (4.75%)

Add to watchlist

Market Trend

		Short Term	Medium Term
Industry	Biotechnology (US)	Mixed	Bearish
	Biotechnology (Global)	Mixed	Bearish
Stock	Ascendis Pharma A/S	Bullish	Bullish

Stockmoo Score

0.8

Similar Stocks

Stock	Market Cap	DY	P/E	P/B
ASND	7 B	-	-	-
BNTX	30 B	-	-	1.40
BCYC	2 B	-	-	1.62
NMRA	2 B	-	-	4.72
IMCR	2 B	-	-	4.67
AUTL	1 B	-	-	2.06

Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
Sector	Healthcare
Industry	Biotechnology

52 Weeks Range	85.29 (-28%) — 161.00 (35%)
Price Target Range	157.00 (31%) — 264.00 (121%)
High	264.00 (Wells Fargo, 121.44%)	Buy
Median	178.00 (49.30%)
Low	157.00 (TD Cowen, 31.69%)	Buy
Average	186.67 (56.58%)
Total	9 Buy
Avg. Price @ Call	123.89

Firm	Date	Target Price	Call	Price @ Call
Cantor Fitzgerald	16 Sep 2024	170.00 (42.59%)	Buy	119.22
Cantor Fitzgerald	09 Sep 2024	170.00 (42.59%)	Buy	116.84
Oppenheimer	05 Sep 2024	180.00 (50.98%)	Buy	119.00
B of A Securities	04 Sep 2024	175.00 (46.79%)	Buy	119.50
Citigroup	04 Sep 2024	178.00 (49.30%)	Buy	119.50
JP Morgan	04 Sep 2024	165.00 (38.40%)	Buy	119.50
JP Morgan	21 Aug 2024	174.00 (45.95%)	Buy	137.00
TD Cowen	04 Sep 2024	157.00 (31.69%)	Buy	119.50
TD Cowen	25 Jun 2024	175.00 (46.79%)	Buy	135.79
Wells Fargo	04 Sep 2024	264.00 (121.44%)	Buy	119.50
Goldman Sachs	13 Aug 2024	195.00 (63.56%)	Buy	139.66
Jefferies	13 Aug 2024	196.00 (64.40%)	Buy	139.66
Show more

No data within this time range.

Date	Type	Details
16 Sep 2024	Announcement	Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to Placebo
13 Sep 2024	Announcement	Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024
11 Sep 2024	Announcement	Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in Adults
03 Sep 2024	Announcement	Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
03 Sep 2024	Announcement	Ascendis Pharma Reports Second Quarter 2024 Financial Results
28 Aug 2024	Announcement	Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024
12 Aug 2024	Announcement	VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism
12 Aug 2024	Announcement	FDA Approves YORVIPATH® (Palopegteriparatide) as the First and Only Treatment for Hypoparathyroidism in Adults
24 Jun 2024	Announcement	Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2024	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)